Neuralink Receives Canadian Approval for Brain Chip Clinical Trial
核心洞察
Neuralink (搜索) has been approved to begin its first clinical trial in Canada, focusing on a brain chip designed to enable paralyzed individuals to control digital devices with their thoughts.
The Canadian study will assess the safety and initial functionality of Neuralink (搜索)'s implant in individuals with quadriplegia (搜索), allowing them to control external devices using their thoughts.
University Health Network in Toronto has been selected to perform the neurosurgical procedure for the Canadian clinical trial, marking a significant step in Neuralink (搜索)'s expansion.
Neuralink (搜索), Elon Musk's brain-computer interface company, has received approval to launch its first clinical trial in Canada. The trial will focus on a device designed to enable paralyzed individuals to control digital devices simply by thinking. This marks a significant step for the company as it expands its research efforts beyond the United States.
The Canadian study aims to evaluate the safety and initial functionality of Neuralink (搜索)'s implant. The device is intended for individuals with quadriplegia (搜索), or paralysis of all four limbs, and seeks to restore their ability to interact with external devices through thought control. The University Health Network in Toronto has been selected to conduct the complex neurosurgical procedure.
Prior Neuralink Implants
In the United States, Neuralink (搜索) has already implanted the device in two patients. According to the company, the second trial patient has been using the implant to play video games and learn how to design 3D objects, demonstrating the potential of the technology to restore functionality.
Neuralink's Vision
Founded in 2016, Neuralink (搜索) is developing a brain chip interface that can be implanted within the skull. The company envisions that this technology could eventually help disabled patients regain movement and communication abilities, as well as restore vision. In September, Neuralink received the U.S. Food and Drug Administration's "breakthrough device" designation for its experimental implant aimed at restoring vision.